Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions
- UCSD Department of Ophthalmology, Shiley Eye Center, Joan and Irwin Jacobs Retina Center, La Jolla, CA, USA
- Dr W R Freeman, UCSD Department of Ophthalmology, Shiley Eye Center, 0946, Joan and Irwin Jacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA 92037, USA; freeman{at}eyecenter.ucsd.edu
- Accepted 6 January 2008
We read with great interest the article “Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions,” by Lux et al.1 Avastin and Lucentis have become the standard of care for choroidal neovascularisation with a better visual acuity outcome than other well-studied therapies.2 3 The use of Macugen and photodynamic therapy (PDT) is declining rapidly. The current challenge with the new anti-vascular endothelial growth factor treatment is to determine which eyes do and do not respond to …
